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Results of NOPHO ALL2008 treatment for patients aged
1–45 years with acute lymphoblastic leukemia
N Toft1,2, H Birgens1, J Abrahamsson3, L Griškevičius4, H Hallböök5, M Heyman6, TW Klausen1, ÓG Jónsson7, K Palk8, K Pruunsild9,
P Quist-Paulsen10, G Vaitkeviciene11, K Vettenranta12, A Åsberg13, TL Frandsen14, HV Marquart15, HO Madsen15, U Norén-Nyström16
and K Schmiegelow14,17
Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated
1509 consecutive patients aged 1–45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without
cranial irradiation. Overall, 1022 patients were of age 1–9 years (A), 266 were 10–17 years (B) and 221 were 18–45 years (C). Sixteen
patients (three adults) died during induction. All others achieved remission after induction or 1–3 intensive blocks. Subsequently, 45
patients (12 adults) died, 122 patients relapsed (32 adults) with a median time to relapse of 1.6 years and 13 (no adult) developed a
second malignancy. Median follow-up time was 4.6 years. Among the three age groups, older patients more often had higher risk
ALL due to T-ALL (32%/25%/9%, Po0.001), KMT2A rearrangements (6%/5%/3%, Po0.001) and higher day 29 residual leukemia for
B-lineage (Po0.001), but not T-ALL (P= 0.53). Event-free survival rates (pEFS5y) were 89 ± 1% (A), 80 ± 3% (B) and 74± 4% (C) with
signiﬁcant differences only for non-high risk groups. Except for thrombosis, pancreatitis and osteonecrosis, the risk of 19 speciﬁed
toxicities was not enhanced by age above 10 years. In conclusion, a pediatric-based protocol is tolerable and effective for young
adults, despite their increased frequency of higher risk features.
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INTRODUCTION
The cure rate for childhood acute lymphoblastic leukemia (ALL) is
above 85% with the best contemporary treatment,1 whereas
outcome for ALL in adults has lagged signiﬁcantly behind despite
intensiﬁed chemotherapy and frequent use of hematopoietic stem
cell transplantation (hSCT).2–5 The use of pediatric-inspired
treatment regimens has provided improvement for young adult
patients,6–11 but the upper age limit for tolerance to such
intensive antileukemic therapy is still uncertain, and the higher
risk of relapse for adults with ALL has led to extensive use of hSCT.
When relapse or refractory disease occurs in adults, the outcome is
dismal.12 The superior cure rate for children13 has been suggested
to reﬂect differences in disease biology, including molecular
genetics,14 drugs administered, as well as patient adherence to
treatment guidelines.15 However, reliable comparisons of outcome
have been hampered by the use of different diagnostic strategies,
risk-grouping criteria and treatment protocols. To overcome these
obstacles, common diagnostic work-up, risk grouping and therapy
for newly diagnosed Philadelphia chromosome-negative patients
aged 1–45 years with ALL since July 2008 have been implemented
with the use of the NOPHO ALL2008 protocol in Denmark, Estonia,
Finland (adults included from 2015), Iceland (children only),
Lithuania, Norway and Sweden.16,17 Diagnostics, treatment,
toxicity and outcome data are prospectively registered in a
common database.17 We here present cure and toxicity rates in
risk group-stratiﬁed analyses for 1509 childhood, and adult ALL
patients reported as an observational study.
MATERIALS AND METHODS
Patients
From July 2008 to December 2014, the Nordic Society of Pediatric
Hematology and Oncology (NOPHO) ALL2008 protocol has recruited newly
diagnosed patients aged 1–45 years with Philadelphia chromosome-
negative B-cell precursor (BCP) or T-lineage ALL. Patients with Down’s
syndrome were excluded. The protocol did not open simultaneously in all
centers, but once opened, all consecutive patients were included
(Supplementary Table S1; Supplementary Appendix, page 2). The 1509
study patients (Figure 1) were registered in a common database and
systematically updated with respect to disease characteristics, treatment
response, outcome and 19 pre-selected toxicities at least every 3 months.
Adherence to the protocol was facilitated by online data entry at diagnosis,
treatment day 15, end of induction (day 29) and at the end of early
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consolidation (day 79), which then automatically provided information to
the treating physician on protocol risk-group assessment and treatment
allocation. In addition, patient-related questions from any participating
center could be entered into an online ‘help-desk’ function, which were
distributed by automated e-mails to all national pediatric and adult
NOPHO ALL2008 principal investigators with rapid online feedback
including treatment recommendations to the treating center. The regional
or national ethics committees approved the protocol, and informed
consent was obtained according to the Declaration of Helsinki. Adult and
Baltic patients did not participate in the three randomized studies
(Supplementary Table S2; Supplementary Appendix, page 4) registered
with Eudract number 2008-003235-02 and at clinicaltrials.gov
(NCT01678508, NCT00819351, NCT00991744).
Protocol design
NOPHO ALL2008 remission induction therapy and risk-group stratiﬁcation.
On the basis of leukemia characteristics at diagnosis and minimal residual
disease in bone marrow (MRD) after induction therapy (vincristine,
doxorubicin, glucocorticosteroid, intrathecal methotrexate) on days 15
and 29, and after consolidation therapy day 79 (or after HR-ALL blocks A1
and B1, see below), patients were assigned to standard risk (SR),
intermediate risk (IR), high risk (HR), or HR therapy with hSCT indicated
by poor response at MRD time points day 29 (⩾5%) or day 79 or post-block
B1 (⩾0.1%) (Figures 1 and 2).16 Except for a difference in the capping dose
of vincristine (2.5 mg for patients o18 years at diagnosis; otherwise 2 mg)
and an option for adult patients to be offered hSCT in case of translocation
t(4;11)[KMT2A/AFF1], the treatment within each risk group was indepen-
dent of patient age. Patients with SR and IR ALL received conventional
post-induction ALL therapy with one or two delayed intensiﬁcations,
respectively, whereas patients with HR-ALL received seven to nine very
intensive ALL blocks in addition to delayed intensiﬁcation and main-
tenance therapy. The number of HR blocks was determined by MRD after
block A1. If MRD was o0.1%, the patients received seven HR blocks in
total (only one C block) otherwise they continued with all nine blocks. The
criteria for hSCT were MRD day 29 ⩾ 5%, day 79 ⩾ 0.1% or post-block
B1 ⩾ 0.1%. It was optional for adult clinicians to transplant patients with
hypodiploidy or KMT2A-r. For patients allocated to HR or HR with hSCT
therapy, the ﬁrst three blocks would always be A1-B1-C1.
Oral mercaptopurine/methotrexate maintenance therapy was for all
non-transplanted patients continued until 2.5 years from diagnosis
(Supplementary Table S3; Supplementary Appendix, page 8). MRD was
measured by RQ-PCR-based techniques using patient-speciﬁc clonal Ig/TCR
gene rearrangements according to the BIOMED-2 guidelines18,19 and/or by
ﬂow cytometry using protocol-deﬁned six-color MRD panels for identiﬁca-
tion and monitoring of leukemia-associated immunophenotypes as
deﬁned by the NOPHO ALL-2000 guidelines.20 According to the NOPHO
ALL2008 protocol, BCP-ALL was risk group stratiﬁed by ﬂow cytometry, and
T-ALL by PCR assessment of clonal immune gene rearrangements, if
informative markers were available (otherwise the alternative method
was used).
Statistical analysis
Differences in the distribution of individual parameters were analyzed
using the χ2 test or Fisher’s exact test for categorical variables and one-way
ANOVA for continuous variables. Spearman’s correlation coefﬁcient (rs) was
used to identify possible associations for continuous variables. The Kaplan–
Meier method was used to estimate probability of event-free survival
(pEFS) and overall survival (pOS) rates, and differences were compared
with the 2-sided log-rank test. For the HR-hSCT group lack of harmonized
strategies across both pediatric and adult centers for donor identiﬁcation,
conditioning regimens and supportive care were missing which hampers
reliable outcome analyses. The HR and HR-hSCT patients were thus pooled
(HR w/wo hSCT) and the follow-up of patients stratiﬁed to hSCT was
truncated 2 weeks prior to the hSCT date in the combined survival
analyses. The duration of EFS was deﬁned as the time from diagnosis until
ﬁrst occurrence of induction death, relapse, death in remission, develop-
ment of a second malignancy, date of hSCT minus 2 weeks for the HR-hSCT
patients or the last known follow-up for patients without events. The
duration of OS was deﬁned as time from diagnosis to death. Death in
complete remission (DRC1) was deﬁned as death without evidence of
leukemia or a second malignancy. The Cox proportional hazard model was
used for calculating hazard ratios (HR) with corresponding conﬁdence
limits with Wald test for P-values.
For patients in complete remission, the cumulative risk of any relapse, of
isolated central nervous system (CNS), testicular relapse, therapy-related
second malignancy or of toxic death were estimated by using a cumulative
incidence perspective treating the events as competing events. P-values
were calculated using the Gray’s test. For regression modeling, a Fine-Gray
model was used for calculating parameter estimates and P-values.21
Patients could change risk-group allocation until treatment day 79 (or
post-block B1 for HR-ALL). When analyzing time to event within a risk
group, patients were censored when allocated to another risk group and
had entry to the new risk group at allocation. Equally in analyses on the
entire cohort adjusting for risk-group allocation, risk-group allocation was
treated as a time-dependent covariate.
The proportional hazard assumptions were investigated using scaled
Schoenfeld residuals. All the analyses were based on intention to treat.
Statistical examination was carried out using the R (R Foundation for
Statistical Computing, Vienna, Austria) version 3.2.3 and Statistical
Packages for Social Sciences (SPSS, Chicago, IL, USA) software, version
22.0.0. Fine-Gray models and calculations including time-dependent
covariates were performed using the R ‘survival’ package. All tests were
two-sided with Po0.05 considered statistically signiﬁcant.
RESULTS
Of 834 males and 675 females, 1278 had BCP-ALL and 231T ALL
(Table 1). T-ALL was rarer in patients aged 1–9 years than those
aged 10–17 and 18–45 years (9, 25 and 32%; Po0.001), with no
signiﬁcant difference between the two oldest age groups
(P= 0.09). Age and WBC at diagnosis were inversely correlated in
both BCP-ALL (rs =− 0.17, Po0.001) and T-ALL (rs =− 0.28;
Po0.001). Among BCP-ALL patients, the three age groups did
not differ with regard to the proportion of patients with WBC
⩾ 100 × 109 per liter (8%, 9%, 9%, P= 0.85), whereas the fraction of
T-ALL patients with WBC ⩾ 100 × 109 per liter decreased sig-
niﬁcantly with increasing age (55%, 40%, 30%; P= 0.006). The
presence of risk stratifying karyotypes differed signiﬁcantly
between the three age groups (Table 1).
Risk-group distribution
Owing to a higher frequency of T-cell ALL, KMT2A-r and poorer MRD
response to induction therapy (Figure 3a), older patients were more
Figure 1. Consort diagram ALL patients 1–45 years. Stem cell
transplantation was optional for patients with hypodiploidy. ID,
induction death; NA, not available for risk grouping. *Number of
patients in age groups 1–9/10–17/18–45 years.
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often allocated to higher risk groups (Table 1; Supplementary
Figure S1; Supplementary Appendix, page 15). Thus, 53.5% of all
children o10 years of age were stratiﬁed to SR therapy and 11.7%
to HR w/wo hSCT, whereas only 20% of adults were stratiﬁed to SR
therapy, but 31% to HR w/wo hSCT (Figure 3b).
Hematopoietic stem cell transplantation
One hundred patients were eligible for hSCT in ﬁrst remission based
on MRD levels measured on day 29/post A1 (n=61) or day 79/post-
B1 (n=39). Of these 100 patients, 18 were not transplanted due to
relapse (n=3) or death in remission before hSCT could be performed
(n=2), no available donor (n=1), 46 months to identify a donor
and hSCT was then not chosen (n=1), severe invasive fungal
infection (n=2), parents’ refusal (n=1) or the patient was treated as
IR (n=7) or HR (n=1) due to decision by the treating physician
because of MRD borderline values for risk-group assignment. Only
one of the latter eight patients had a relapse. The median time from
diagnosis to transplantation for the remaining 82 hSCT patients was
175 days and not inﬂuenced by age group (P=0.55).
In addition, three patients with hypodiploidy (two adults and
one child) and six patients with KMT2A-r (four adults and two
children) were transplanted at the discretion of the treating
physician, none of whom had an MRD indication for hSCT.
An additional 16 patients not fulﬁlling the protocols transplan-
tation criteria were transplanted due to (i) MRD being only just
below the threshold on day 29 (n= 2) or after day 79/post-B1 (or
later) (n= 7), (ii) severe toxicity during block treatment (n= 1),
strong request by an HR adult patient (n= 1), (iii) T-ALL with day 29
PCR-based MRD 45% but ﬂow cytometry-based MRD o5%
(n= 3), (iv) classiﬁcation as hypodiploidy although with an
incomplete karyotype harboring t(12;21)[ETV6/RUNX1] with DNA-
index of 1 by ﬂow cytometry (n= 1) or (v) severe and persistent
bone marrow aplasia after the B2 HR block (n= 1). No change in
the overall pEFS was found when these 16 patients were censored
at the time of hSCT.
Events
After a median follow-up for patients in ﬁrst remission of 4.6 years
(IQR range: 3–6.4 years), the 5-year pEFS (pEFS5y) and overall
survival for the whole cohort was 85 ± 1% and 91 ± 1%,
respectively (Figure 4a; Table 2). The risk of induction death
(N= 16, three adults) did not differ signiﬁcantly between the three
age groups (P= 0.87). Of the remaining 1493 patients, one patient
moved abroad during induction therapy, four patients had no
MRD marker and two patients could not be risk grouped because
of profound treatment changes including severe delays in therapy
due to toxicity, and all other patients achieved complete remission
(MRD o5%) after induction therapy (n= 1376), post HR block A1
(including patients shifted directly to block therapy day 15; n= 85),
post HR block B1 (n= 21) or post HR block C1 (n= 4). No patient
died during block therapy prior to obtaining complete remission.
The 45 patients who died during remission were skewed towards
patients older than 10 years (P= 0.008) in overall but not in risk
group-adjusted analyses (P= 0.19).
Despite risk group-adapted therapy, the stratifying parameters
(except for IR stratifying cytogenetics and KMT2A-r (P= 0.059))
were signiﬁcantly associated with inferior EFS in univariate
analyses, that is, higher white blood cell count (WBC)
(Po0.001), T-ALL immunophenotype (Po0.001), CNS involve-
ment (P= 0.022) and hypodiploidy (Po0.001). These parameters
co-varied signiﬁcantly with each other (Supplementary Table S4;
Supplementary Appendix, page 16)
In total, 122 patients developed a relapse after a median of 1.6
years (range: 0.11–6.6 years) from diagnosis (Table 2) of which 34
(30%) involved the CNS (22 isolated) with no signiﬁcant difference
in CNS involvement between age groups (overall P= 0.12).
The impact of age on pEFS and relapse risk differed between
risk groups (Figure 4a). In both the SR and IR group, adults did
signiﬁcantly worse than patients aged 1–9 years of age, but did
not differ signiﬁcantly from patients aged 10–17 years (Figure 4a).
For the HR patients with or without an indication for hSCT, no
signiﬁcant difference in pEFS5y was seen between the three age
Figure 2. NOPHO 2008 protocol overview. MRD, minimal residual disease; BM d0, 15, 29 and 79, bone marrow day 0, 15, 29, 79; PreB precursor,
B-ALL; T, T-ALL; I-D, induction with dexamethasone; I-P, induction with prednisolone; DI, delayed intensiﬁcation; SR, standard risk; IR,
intermediate risk; HR, high risk; SCT, hematopoietic stem cell transplantation; HD MTX, high-dose methotrexate; 6MP, 6-mercaptopurine; VCR,
vincristine; AraC, cytarabine; Dexa, dexamethasone; pred, prednisolone; TIT, triple intrathecal treatment.
Common all treatment strategy in patients aged 1–45 years
N Toft et al
608
Leukemia (2018) 606 – 615 © 2018 Macmillan Publishers Limited, part of Springer Nature.
Table 1. Demographic data for 1509 ALL patients aged 1–45 years
Age group 1–9 10–17 18–45 All P pEFS± s.e. (5 years)
All 1022 (67.7%) 266 (17.6%) 221 (14.6%) 1509 (100%) 0.84± 0.01
Sex
Male 538 (52.6%) 160 (60.2%) 136 (61.5%) 834 (55.3%) 0.012 0.84± 0.01
Female 484 (47.4%) 106 (39.8%) 85 (38.5%) 675 (44.7%) 0.84± 0.02
Cell lineage
BCP 929 (90.9%) 199 (74.8%) 150 (67.9%) 1278 (84.7%) o0.001 0.86± 0.01
T 93 (9.1%) 67 (25.2%) 71 (32.1%) 231 (15.3%) 0.74± 0.03
WBC
o100 897 (87.8%) 221 (83.1%) 182 (84.3%) 1300 (86.4%) 0.094 0.86± 0.01
⩾ 100 125 (12.2%) 45 (16.9%) 34 (15.7%) 204 (13.6%) 0.70± 0.03
WBCa 11.8 (4.9; 40.8) 9.7 (4; 59.6) 12.8 (4.1; 46.3) 11.6 (4.6; 44) 0.92 —
Missingb 0 0 1 1
WBC (BCP) 9.9 (4.6; 30.4) 8.1 (3.5; 30.1) 6.8 (2.9; 27) 9.1 (4.2;30) 0.013 —
Missing 0 0 1 1
WBC (T) 134 (40;316) 71.7 (8.8; 249) 38.8 (14.4; 112) 76.3 (18.6; 226) o0.001 —
Hgb (g/l)a 72 (57; 87) 87 (70; 108) 96 (79; 118) 78 (61; 95) o0.001 —
Missing 1 0 2 3
Plateletsa 43 (20; 103) 55 (27; 118) 55 (26; 117) 47 (26; 115) 0.004 —
Missing 0 0 2 2
CNS status
CNS 1 888 (87.1%) 233 (87.9%) 198 (92.1%) 1319 (88%) 0.12 0.85± 0.01
CNS 2 91 (8.9%) 17 (6.4%) 11 (5.1%) 119 (7.9%) 0.80± 0.04
CNS 3 40 (3.9%) 15 (5.7%) 6 (2.8%) 61 (4.1%) 0.72± 0.06
Missing 3 1 6 10
t(12;21)
Present 287 (28.5%) 16 (6.1%) 4 (1.9%) 307 (20.8%) o0.001 0.91± 0.02
Absent 720 (71.5%) 246 (93.9%) 204 (98.1%) 1170 (79.2%) 0.82± 0.01
Not analyzed 13 4 10 27
Missing 2 0 3 5
Hyperdiploid
Present 336 (38.4%) 42 (19.4%) 23 (13%) 401 (31.6%) o0.001 0.88± 0.01
Absent 540 (61.6%) 174 (80.6%) 154 (87%) 868 (68.4%) 0.82± 0.01
Not analyzed 22 5 14 41
Missing 124 45 30 199
t(1;19)
Present 32 (3.1%) 9 (3.4%) 9 (4.2%) 50 (3.3%) 0.72 0.96± 0.03
Absent 986 (96.9%) 257 (96.6%) 203 (95.8%) 1446 (96.7%) 0.84± 0.01
Not analyzed 4 0 7 11
Missing 0 0 2 2
iAmp21
Present 15 (1.5%) 15 (5.8%) 4 (2%) 34 (2.3%) o0.001c 0.61± 0.12
Absent 984 (98.5%) 244 (94.2%) 197 (98%) 1425 (97.7%) 0.85± 0.01
Not analyzed 22 7 18 47
Missing 1 0 2 3
dic(9;20)
Present 22 (2.2%) 1 (0.4%) 2 (1.1%) 25 (1.7%) 0.11c 0.89± 0.08
Absent 975 (97.8%) 260 (99.6%) 187 (98.9%) 1422 (98.3%) 0.84± 0.01
Not analyzed 24 5 29 58
Missing 1 0 3 4
KMT2A-r
Present 29 (2.8%) 14 (5.3%) 14 (6.5%) 57 (3.8%) 0.015 0.71± 0.06
Absent 990 (97.2%) 252 (94.7%) 201 (93.5%) 1443 (96.2%) 0.85± 0.01
Not analyzed 3 0 6 9
Hypodiploidy d
Present 11 (1.1%) 7 (2.7%) 4 (1.9%) 22 (1.5%) 0.13 0.56± 0.11
Absent 1008 (98.9%) 256 (97.3%) 144 (98.4%) 1473 (98.5%) 0.84± 0.01
Not analyzed 3 3 8 14
Abbreviations: 5y, ﬁve year; ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; CNS, central nervous system; dic(920), dicentric chromosomal aberration
(920); EFS, event-free survival; Hgb, hemoglobin; iAmp21, intrachromosomal ampliﬁcation of chromosome 21; KMT2A-r, lysine [K]-speciﬁc methyltransferase 2A;
s.e., standard error; t(119), translocation (119); WBC, white blood cell count. aMedian (IQR) and one-way ANOVA. bOne patient has missing value for but
conﬁrmed from center to be below 100. cFisher’s exact test due to low cell counts. dHypodiploidy, according to karyotype and DNA-index by ﬂow cytometry.
Tests are χ2 except when stated otherwise. Unknown and missing patient status is not included in analyses.
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groups (pEFS5y: 70 ± 4%, 70 ± 5%, 61 ± 6%, respectively, P= 0.45).
When comparing the HR patients who had survived until the
median time to hSCT (175 days) and who had or had not an
indication for hSCT, we found no difference in their pEFS5y, and
that was the case both for patients aged 1–17 years (79 ± 6% vs
71± 4%, P= 0.23) and for adults (68 ± 7% vs 60 ± 11%, P= 0.96).
Furthermore, we found no overall signiﬁcant difference between
transplanted children and adults (P= 0.2) and no difference
between non-transplanted children and adults in the HR group
(P=0.57). Regarding treatment-related mortality (TRM), the trans-
planted cohort was small (n=82 of which n=55 were 1–17 years,
n=27 were 18–45 years) and data should be interpreted with
caution. In this study, we found no difference in TRM for children
aged 1–17 years who were transplanted compared with non-
transplanted children (9±4% vs 7± 2%, P=0.73) and no difference
in the adult group either (0 ± 0% vs 10± 4%, P=0.1). In addition,
there was no difference between children and adults in neither the
transplanted group (P=0.11) nor the non-transplanted group
Figure 3. Early response (a) and risk-group distribution (b). (a) MRD day 29/post-block A1. Of 1509 patients, 16 suffered from induction death,
2 were without risk groups, 7 had no MRD value day 29/post-block A1 and 27 have missing exact values. MRD values of 10− 5 or lower are
considered MRD negative. (b) Final risk group distribution d79/post-block B1 for six age groups: 1–4, 5–9, 10–14, 15–17, 18–25 and 26–45
years. Standard risk (SR), intermediate risk (IR), high risk (HR) and high risk with stem cell transplantation in ﬁrst remission (SCT).
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Figure 4. Response (a) and toxicity (b). (a) Projected event-free survival (pEFS), cumulative relapse and cumulative death in complete ﬁrst
remission (Cum. DCR1) in 1509 patients. Projected event-free survival (pEFS) in the four risk groups (b). Distribution of the 11 most common
registered toxicities (n450 observations), odds ratio (OR) and trend analysis with conﬁdent intervals and P-values adjusted for risk group. PCP,
Pneumocystis pneumonia; PRES, posterior reversible encephalopathy syndrome.
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Table 2. Treatment outcome, pEFS, OS and cumulative risks for 1509 ALL patients aged 1–45 years
Age group 1–9 10–17 18–45 Total Pa
N 1022 266 221 1509
Continuous CR1 920 220 174 1314
Induction death (ID) 10 3 3 16
Relapse
BM only 31 16 16 63
CNS only 11 7 4 22
Testis only 0 0 3 3
BM+CNS 9 1 0 10
BM+T 1 0 0 1
BM+CNS+T 2 0 0 2
BM+other 0 0 3 3
Other 1 1 1 3
Total relapse 61 29 32 122
SMN 10 2 0 12
DCR1 21 12 12 45
Median follow-up (years)b 4.9 4.6 3.2 4.6
Induction death 0.01± 0.00 0.01± 0.01 0.01± 0.01 0.01± 0.00 0.87
Relapse CNS (5 years) 0.01± 0.00 0.03± 0.01 0.03± 0.01 0.02± 0.00 0.12
Relapse other/BM (5 years) 0.06± 0.01 0.10± 0.02 0.16± 0.03 0.08± 0.01 o0.001
SMN (5 years) 0.01± 0.00 0.01± 0.01 0.00± 0.00 0.01± 0.00 0.42
DCR1 (5 years) 0.02± 0.00 0.05± 0.01 0.06± 0.02 0.03± 0.00 0.006
Any relapse (5 years)c 0.07± 0.01 0.13± 0.02 0.19± 0.03 0.10± 0.01 o0.001
Other event (5 years)c 0.04± 0.01 0.07± 0.02 0.08± 0.02 0.05± 0.01 0.046
Fine-Gray modelf
Relapse (HRa) 1 (ref ) 2.0 (1.3; 3.2) 3.4 (2.2;5.2)
Relapse (P) 0.002 o0.001 o0.001
DCR1 (HRa) 1 (ref ) 2.3 (1.1; 4.7) 2.9 (1.4; 5.9)
DCR1 (P) 0.019 0.003 0.005
pEFS
5 years 0.89± 0.01 0.80± 0.03 0.74± 0.04 0.85± 0.01
HRa (95% CI) 1 (ref ) 2.0 (1.4; 2.8) 2.8 (2.0; 4.0)
P o0.001 o0.001 o0.001
Adjusted-HRad 1 (ref ) 1.7 (1.1;2.2) 2.2 (1.5; 3.3)
Adjusted-Pd 0.008 o0.001 o0.001
OS
5 years 0.94± 0.01 0.87± 0.02 0.78± 0.03 0.91± 0.01
HRa (95% CI) 1 (ref ) 2.3 (1.5; 3.5) 3.8 (2.5; 5.7)
P o0.001 o0.001 o0.001
Adjusted-HRad 1 (ref ) 1.7 (1.1;2.8) 2.8 (1.8;4.4)
Adjusted-Pd 0.021 o0.001 o0.001
SR
Ne 547 82 44 673
pEFS, 5 years 0.93± 0.01 0.86± 0.04 0.82± 0.07 0.91± 0.01
pEFS, HRa (95% CI) 1 2.1 (1.0; 4.3) 2.6 (1.1; 6.2)
pEFS, P 0.038 0.030 0.022
FGM, DCR1, (HRa) 2.2 (0.4; 11.0) 2.1 (0.3; 17.7)
FGM, DCR1, (P) 0.33 0.48 0.54
FGM, relaps, (HRa) 2.6 (1.1; 6.2) 4.0 (1.5; 10.6)
FGM, relaps (P) 0.028 0.006 0.006
IR
N 344 104 94 542
pEFS, 5 years 0.91± 0.02 0.83± 0.04 0.77± 0.05 0.87± 0.02
pEFS, HRa (95% CI) 1 1.9 (1; 3.5) 3.2 (1.8; 5.6)
pEFS, P 0.039 o0.001 o0.001
FGM, DCR1 (HRa) 1 1.9 (0.6; 6.5) 2.6 (0.8; 8.2)
FGM, DCR1 (P) 0.31 0.10 0.24
FGM, relaps (HRa) 1 2.0 (1.0; 4.1) 3.4 (1.8; 6.7)
FGM, relaps (P) 0.062 o0.001 0.001
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(P=0.82). Focusing on relapses, we found no difference between
children aged 1–17 years who were transplanted compared with
non-transplanted children (12±5% vs 21±4%, P=0.10) and no
difference in the adult group either (40±11% vs 19±6%, P=0.56).
However, a signiﬁcant difference in risk of relapse was found
between children and adults in the transplanted group (P=0.01),
but not in the non-transplanted group (P=0.42). When looking at
the latest MRD value available (post-block C1) for the 82 HR patients
who were transplanted, there was for the whole group an increased
HR with increasing MRD: HR 1.5 (95% CI: 1.1–2.1), P=0.007 (HR per
10-fold increment in MRD).
For all patients, there were no increase in the rate of DCR1 for
adolescents and adults (HR (10–17 years): 1.8, HR (18–45 years): 0.9,
overall P=0.29) (Table 2). Among the 45 patients aged 1–17 years
with MRD day 29, ⩾ 5% the risk group-based strategy yielded a
pEFS5y of 79±6%, whereas for the 18 patients aged 18–45 years,
the pEFS5y was 48± 12% (P=0.01). When adult patients were
divided into age groups 18–25 (n=110) and 26–45 years (n=111),
no signiﬁcant difference in pEFS5y was found (77± 4% and 69±5%,
respectively, P=0.60). Furthermore, neither risk of induction death
(P=0.57), relapse (P=0.98), remission death (P=0.53) nor SMN (no
events) differed between these two adult groups (Supplementary
Table S5; Supplementary Appendix, page 20).
Toxicity
The incidences of 19 speciﬁed toxicities (Supplementary Table S6;
Supplementary Appendix, page 21) were very similar for children and
adults,22 except for the risk of thrombosis (Po0.001), pancreatitis
(Po0.001) and osteonecrosis (Po0.001), which was higher for
patients X10 years (Figure 4b; Supplementary Table S7;
Supplementary Appendix, page 23). In contrast, the risk of
asparaginase-associated allergic reaction was signiﬁcantly higher for
children below 10 years compared with older patients (Po0.001).
Data from the randomized asparaginase study for patients aged 1–17
years are being analyzed and will be published separately. Finally, as
a composite parameter of the toxicity burden, not least duration of
myelosuppression, the interval between the treatment phases was
almost identical for the three age groups (data not shown).22
DISCUSSION
The population-based use of a common treatment protocol for
this, so far, largest published consecutive cohort of ALL patients
aged 1–45 years adds important data to recent reports on such
patients.2,23–25 Previously, the superior outcome of children has
been suggested to be linked to disease biology, treatment
intensity, differences in chemosensitivity, frequency of toxicity
leading to treatment modiﬁcation, as well as physician compliance
and patient adherence to protocol guidelines.
Compared with previous adult ALL regimens, the NOPHO
ALL2008 protocol is less intensive with respect to induction
treatment and SR therapy, but more intensive for HR treatment,
although entirely omitting cranial irradiation. However, two of the
most important differences between previous adult protocols and
the NOPHO ALL2008 is the extensive use, in all risk groups, of
asparaginase23 and high-dose methotrexate with co-
administration of mercaptopurine,26 which may have contributed
to the effectiveness of the protocol.
The overall worse outcome for adolescents and adults on NOPHO
ALL2008 treatment seems primarily associated with the more
frequent presence of T-cell ALL, KMT2A-r and higher post-induction
MRD.16 The risk-stratiﬁed therapy does not fully compensate for the
adverse prognostic factors. Particularly in the SR/IR group,
adolescents and adult patients have an increased relapse risk
despite good or intermediate response to chemotherapy. However,
compared with the survival in adult patients reported previously on
traditional adult regimes, these results are encouraging regarding
pEFS5y.
2,27–29 Other groups have presented results of adults treated
on pediatric protocols; a US intergroup trial reported 2 years EFS of
66% for patients aged 16–39 years30 compared with EFS2y 84±2%
for our patients aged 16–39 years. In a Dana Faber study of ALL
patients aged 18–50 years treated with a pediatric protocol, the 4
years EFS was 62% for Ph-negative patients24 compared with EFS4y
of 74± 4% in our patients aged 18–45 years. Both studies concluded
that using a pediatric protocol was feasible and our results add
important information to these publications.
The rate of death during induction or in remission for adults was
low compared with historical data2 and did not differ signiﬁcantly
from that reported for pediatric patients.31 This ﬁnding conﬁrms
what was reported in the US intergroup trial (2% treatment-related
mortality)30 as well as the recently published UKALL14 adult study
report of 0/21 induction death in a small group of Ph-negative
patients below 40 years receiving treatment with asparaginase
during induction (treatment-related mortality not presented).32 The
toxicities encountered during the NOPHO ALL2008 protocol
seemed to affect all age groups equally and were strongly
associated with HR treatment (data not shown). However, the risk
of thrombosis, pancreatitis and osteonecrosis was signiﬁcantly
associated with age (410 years)22 and are most likely asparaginase
related. Importantly, the incidence of these toxicities did not differ
for adolescents and adults. The risk of ON in adults was in this
cohort almost comparable with the adult Dana Faber study (for
patients ⩾18 years 5% vs 8.5% in NOPHO ALL2008)24 and similar to
Table 2. (Continued )
Age group 1–9 10–17 18–45 Total Pa
HR w/wo SCT
N 120 76 80 276
pEFS, 5 years 0.70± 0.04 0.70± 0.05 0.61± 0.06 0.67± 0.03
pEFS, HRa (95% CI) 1 1.0 (0.6; 1.7) 1.3 (0.8; 2.2)
pEFS, P 0.91 0.23 0.45
FGM, DCR1 (HRa) 1 1.8 (0.8; 4.2) 0.9 (0.3; 2.5)
FGM, DCR1 (P) 0.19 0.85 0.29
FGM, relaps (HRa) 1 0.7 (0.3; 1.4) 1.4 (0.8; 2.5)
FGM, relaps (P) 0.26 0.23 0.12
Abbreviations: BM, bone marrow; CI, conﬁdence interval; CNS, central nervous system; CR, complete remission; DCR1, death in ﬁrst complete remission; FGM,
Fine and Gray regression model; HR, w/wo hSCT high risk with/without hematopoietic stem cell transplantation; HRa, hazard ratio; IR intermediate risk; OS,
overall survival; pEFS, projected event-free survival; SMN, secondary malignant neoplasm; SR, standard risk. aGray’s test. bFor patients without events. cRelapse:
all locations; other: DCR1, SMN, IF/early death. dAdjusted for risk group assignment as a time-dependent covariate. 18 patients not risk grouped not included.
eN indicates ﬁnal risk assignment. Patients changing risk group where included and censored at time of change in risk assignment. fFine and Gray regression
model. SMN and induction death included in model but results not shown.
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a recent publication by the Dutch pediatric group (8% in patients
aged 10–14 years and 27% in patients aged 15–18 years vs 13.4% in
patients aged 10–17 years in the NOPHO ALL2008).33 The high
incidence in teenagers are well known and may be caused by
extensive use of asparaginase in combination with frequent use of
high-dose MTX and cumulative high doses of dexamethasone. The
lower incidence of ON, thrombosis and pancreatitis in children aged
1–9 years could be explained by a lower cumulative dose of
asparaginase as they may be omitted because of allergic reactions
or due to more silent inactivation. Results of the randomized
NOPHO ALL2008 asparaginase study (Peg-Asparaginase every 2 vs
6 week for patients aged 1–17 years) and investigation of
asparaginase antibodies/silent inactivation are being analyzed and
will be published accordingly. The lower incidence of anaphylactic
reactions in patients above 10 years remains unexplained, however
similar ﬁndings are reported for adults in the Dana Faber study
(5%)24 and the UKALL14 study (4%).32 Except for splitting of
dexamethasone to avoid osteonecrosis,34 little is currently known
how to prevent these acute toxicities associated with ALL therapy.35
In the wake of improved EFS with pediatric-like protocols for
adult ALL, focus on acute and late side effects become increasingly
important, including consensus deﬁnitions of toxicities36 and
capture strategies17 not least for toxicities that harbor a risk of
permanent sequelae such as osteonecrosis,2,34,37 osteoporosis,
chronic pancreatitis38 or diabetes in order to improve the long-
term outcome and quality of life for survivors.35,39
In contrast to the similar treatment outcome for HR w/wo hSCT
patients across age groups, the majority of relapses among adults
with IR ALL occurred while on treatment unlike that of younger
patients who tended to relapse later. This did not seem to depend on
toxicity-driven early treatment delays,22 but could reﬂect both an
increased frequency of other poor prognostic mutations not routinely
included in the diagnostic work-up14 or suboptimal adherence to
maintenance treatment.15,40,41 Few adults were for instance positive
for t(1;19)[TCF3/PBX1], dic(9;20) or iAMP21, and recent studies have
identiﬁed a subgroup of ALL patients with Ph-like alterations that are
more frequent in adults, and have a poor prognosis.14,30,42 Patient
adherence to maintenance treatment is poorly described in adult ALL
patients, but can be measured by levels of the cytotoxic metabolites
of methotrexate and mercaptopurine.34,41,43
Future protocols for both pediatricians and adult hematologists
are expected to focus more extensively on novel driver and
pharmacogenetic mutations, adherence to maintenance treat-
ment, use of immunotherapy, pathway-targeted therapy or less
toxic drug combinations to improve efﬁcacy and reduce the
burden of treatment.
There are limitations to an observational study as presented in
this paper for adult patients. A randomized study comparing the
previously used adult regimens and the NOPHO ALL2008 protocol
was considered unethical due to the inferior results derived from
such therapy.2 Patients allocated to HR w/wo hSCT group needs
further investigation before conclusions can be drawn as
conditioning regimes vary between centers even within the same
country, and there is still no common strategy for pediatricians
and adult hematologists. However, for a small subgroup of
patients with a very poor response to induction therapy (MRD day
29 ⩾ 5%) stratifying them to hSCT, the risk group-based strategy
resulted in EFS5y of 79 ± 6% for patients aged 1–17 years, which is
a notable improvement compared with 45 ± 7% in the previous
NOPHO ALL-2000 protocol.4 These results are comparable with the
Dutch pediatric study showing EFS5y of 78 ± 8% for patients with
poor end of induction response.33 For NOPHO patients aged
18–45 years with a poor end of induction response, the EFS5y was
only 48 ± 12%, but MRD-based historical comparison data are not
available. In a large adult UK/US study (15–55 years), transplanting
all patients with an available donor the high risk-transplanted
patients had an OS5y of 41 vs 35% for those on chemotherapy
alone (no EFS given). This was based on an adult treatment
regime, and showed in addition for all Ph-negative patients an
OS5y of 43%. However, patient ages were higher (15–64 years) and
the data are thus not completely comparable.5
Adult patients from Finland started recruiting later as the
previous adult protocol had acceptable results compared to
similar traditional adult protocols. In Iceland, only 1–2 adult
patients with ALL are diagnosed each year and are not registered
in the database. Both countries are similar to the remaining
countries regarding health care systems and treatment availability
for children and adult patients, thus we consider the results to be
representative for all children and adult patients in the involved
countries.
In conclusion, a common ALL strategy for adult and pediatric
hematologists has shown to be feasible, it revealed similarities
between teenagers and young adults and improved outcome for
adults, while at the same time building a platform for future
common research. Thus, the study highlights the need for risk
group-stratiﬁed comparisons of age deﬁned subsets for reliable
and useful future outcome interpretations.
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